Search Results for "ATTR-CM"

Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.

More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.

For more information about our FDA-approved therapies, please see the Full Prescribing Information:

Evidence of Fewer Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran Compared with Placebo: Analysis from HELIOS-B

Healthcare resource utilization for patients with transthyretin amyloid cardiomyopathy: A real-world study in Europe, Canada and Japan

Meta-regression analysis of the association between change in six minute walk distance and survival in transthyretin-mediated amyloidosis with cardiomyopathy

Vutrisiran Improved Outcomes Versus Placebo in Patients with Transthyretin Amyloidosis with Cardiomyopathy and Severe Chronic Kidney Disease: Post Hoc Analysis of HELIOS-B

Real-world experience with therapeutics for ATTR in the Canadian population

Left Atrial Strain and Clinical Outcomes in Transthyretin Amyloidosis with Cardiomyopathy: Insights from the HELIOS-B Trial on Vutrisiran Efficacy

Outpatient Heart Failure Worsening in Patients with Cardiac Transthyretin Amyloidosis: Results from the APOLLO-B Trial

Right Ventricular Free Wall Strain and Clinical Outcomes in Transthyretin Amyloid Cardiomyopathy and Effect of Vutrisiran: The HELIOS-B Study

Efficacy of vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy by baseline health status and quality of life

Effects of Vutrisiran on Measures of Cardiac Structure, Function and Amyloid Burden by Cardiovascular Magnetic Resonance from the HELIOS-B Trial

Cardiovascular Morbidity and Mortality Among ATTR-CM Patients Treated with Tafamidis in the US

Likelihood of disease worsening in patients receiving tafamidis for ATTR amyloidosis with cardiomyopathy (ATTR-CM): A targeted literature review

History of Polyneuropathy and Musculoskeletal Manifestations in Patients with Transthyretin-Mediated Amyloidosis with Cardiomyopathy in APOLLO-B

Unmet Need in a Contemporary Cohort of Tafamidis-Treated Transthyretin Amyloid Cardiomyopathy Patients

Clinical Presentation and Treatment Landscape of Patients with Transthyretin Amyloidosis With Cardiomyopathy: A Real-world Study in Five European Countries and Japan

Real-World Persistency on Tafamidis: An Analysis of US Insurance Claims Data

Impact of vutrisiran on outpatient worsening heart failure in patients with transthyretin amyloidosis with cardiomyopathy in the HELIOS-B trial

TRITON-CM: A Phase 3 Study to Evaluate the Efficacy and Safety of Nucresiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy

Health-related quality of life for patients with transthyretin amyloid cardiomyopathy: A real-world study in Europe, Canada and Japan

Outcomes of the HELIOS-B monotherapy population: A post-hoc analysis censoring data following tafamidis initiation

Vutrisiran reduces all-cause mortality, cardiovascular mortality, and cardiovascular events in patients with transthyretin amyloid cardiomyopathy: Analysis from the HELIOS-B trial

Neurofilament Light Chain in ATTR Amyloidosis with Cardiomyopathy: Analysis from the Phase 3 APOLLO-B Study

Vutrisiran Reduces Days Lost to Death andor Hospitalization Versus Placebo in Patients with Transthyretin Amyloidosis with Cardiomyopathy in the HELIOS-B Trial

Baseline Characteristics of Patients with Transthyretin Cardiac Amyloidosis Enrolled in the Patisiran Expanded Access Program

Maintenance or Improvement of Functional Capacity, Health Status, and Quality of Life with Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy: Data from the HELIOS-B Study

For further information regarding your request, please connect with us by reaching out to your local Medical Science Liaison or contacting our Medical Information team.